Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
I can almost hear you
Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects
Today, it refers specifically to B12 deficiency anemia resulting from antibodies that inhibit B12 absorption
/product/19/3469114/1.jpg?9363)
The exact dose depends on the patients B12 levels, any health issues, and how well they respond to treatment
Research Highlights Animal Studies : Genetically obese rats treated with AOD-9604 showed significant fat loss, confirming its lipolytic effect via 3-adrenergic pathways
